Crystagen 20 mg

Crystagen is a short peptide bioregulator developed within the Khavinson school of peptide research at the Saint Petersburg Institute of Bioregulation and Gerontology. Classified as a synthetic tripeptide with the sequence Glu-Asp-Pro (EDP), Crystagen was developed to investigate how minimal peptide sequences interact with thymus tissue and immune-cell research models. Its compact structure positions Crystagen as a useful research compound for studying tissue-specific peptide signaling in laboratory contexts.

At the cellular and molecular level, Crystagen is studied for its proposed ability to engage with chromatin structure and modulate transcriptional activity within thymic-cell and lymphocyte cell models. Research observations within the Khavinson framework suggest that short bioregulator peptides interact with specific DNA regions to influence the expression of genes associated with thymic hormone synthesis, immune-cell maturation, and lymphocyte chromatin organization. These observations are consistent with the broader proposition that short peptides act as gene-expression regulators within tissues from which their parent peptide complexes were originally extracted.

Research interest in Crystagen centers on thymus-tissue gene expression studies, immune-cell maturation research models, and lymphocyte signaling investigations. Comparative work on tissue-specific bioregulators positions Crystagen alongside other immune-targeted oligopeptides used to explore peptidergic regulation of thymic biology in cell-culture and animal research models (Khavinson V.K., Anisimov V.N., 2009, Advances in Gerontology). Additional reports within the Khavinson tradition describe how the EDP sequence influences gene-expression activation in immune research models, supporting continued laboratory investigation of Crystagen in thymic and immune-system biology research.

The peptide is supplied as a lyophilized powder to ensure optimal stability during storage and handling.

The development of short peptide bioregulators began in the 1970s at the Military Medical Academy in Saint Petersburg, where Professor Vladimir Khavinson and colleagues isolated peptide fractions from animal tissues that appeared to restore organ-specific function in experimental models. This work led to the founding of the Saint Petersburg Institute of Bioregulation and Gerontology and the systematic study of tissue-derived peptide complexes, including the thymic peptide complex from which Crystagen was later derived.

Crystagen was identified within this research program as a synthetic tripeptide bioregulator with the sequence Glu-Asp-Pro (EDP), associated with thymic tissue and immune-cell research models. Subsequent biochemical and molecular investigations explored how this peptide interacts with chromatin and influences gene-expression patterns in thymic and lymphocyte cell systems, supporting the hypothesis that minimal peptide sequences can act as tissue-specific gene-expression modulators within thymic and immune cell models.

Today, Crystagen is positioned within the wider family of Khavinson-school oligopeptides studied for thymus-tissue gene expression, immune-cell maturation research, and lymphocyte signaling research in laboratory contexts.

1. Chromatin Interaction and Gene-Expression Modulation

Within the Khavinson framework, Crystagen is proposed to interact with specific regions of double-stranded DNA and associated chromatin proteins, where it has been reported to influence gene-expression activation in thymic and lymphocyte research models. This proposed mode of action positions Crystagen as a tool for investigating peptide-mediated chromatin remodeling and transcriptional regulation in immune tissues.

2. Thymic-Cell Signaling and Immune-Cell Pathways

Research observations suggest that Crystagen engages with intracellular signaling pathways relevant to thymic-cell function, including pathways associated with thymic hormone expression research and immune-cell maturation research models. These observations make Crystagen a useful compound for exploring tissue-specific peptide signaling in thymic cell-culture systems.

3. Lymphocyte and Immune-Cell Chromatin Research

Comparative work on short peptide bioregulators indicates that the EDP sequence is associated with chromatin-organization changes in lymphocyte cell models, including studies of aged immune cell populations. In lymphocyte research models, Crystagen is investigated for its role in chromatin remodeling studies, transcriptional reactivation research, and age-related immune chromatin organization investigations.

4. Adaptive and Homeostatic Signaling

Khavinson-school bioregulators are described as adaptive peptide regulators that operate under physiological stress conditions. Crystagen is studied for its proposed contribution to thymic-tissue homeostasis research, including models of age-related decline in immune-cell signaling and oxidative stress adaptation.

Research Applications

Conclusion

Crystagen is a Khavinson-school short peptide bioregulator with the sequence Glu-Asp-Pro, studied for its proposed role in thymus-tissue gene expression, immune-cell maturation research, and lymphocyte chromatin research. Its compact tripeptide structure and dual thymic-lymphocyte positioning make Crystagen a valuable laboratory compound for exploring peptidergic regulation of gene expression in research models.

Research Use Disclaimer

This product is intended for research and laboratory use only. It is designed exclusively for in vitro research purposes. All information provided is for educational and research reference only. This product is not intended for human or animal use. It is not a drug, food, or cosmetic and must not be marketed, labeled, or used as such. Use and handling are restricted to trained and qualified professionals.